Get the Stockscreener App
5.00
3.85%
-0.20
After Hours:
5.00
Fennec Pharmaceuticals Inc stock is traded at $5.00, with a volume of 92,563.
It is down -3.85% in the last 24 hours and down -10.23% over the past month.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
See More
Previous Close:
$5.20
Open:
$5.234
24h Volume:
92,563
Relative Volume:
0.99
Market Cap:
$136.41M
Revenue:
$21.25M
Net Income/Loss:
$-16.05M
P/E Ratio:
-5.00
EPS:
-1
Net Cash Flow:
$-17.14M
1W Performance:
-2.15%
1M Performance:
-10.23%
6M Performance:
-55.04%
1Y Performance:
-33.42%
1-Day Range:
$4.87
$5.234
1-Week Range:
$4.77
$5.33
52-Week Range:
$4.77
$11.92
Fennec Pharmaceuticals Inc Stock (FENC) Company Profile
Name
Fennec Pharmaceuticals Inc
Sector
Industry
Phone
(919) 636-4530
Address
PO BOX 13628, RESEARCH TRIANGLE PARK, NC
Fennec Pharmaceuticals Inc Stock (FENC) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Sep-07-22 | Initiated | CapitalOne | Overweight |
| Aug-08-22 | Resumed | Craig Hallum | Buy |
| Jun-05-20 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-11-18 | Initiated | Goldman | Buy |
Fennec Pharmaceuticals Inc Stock (FENC) Latest News
Fennec Pharmaceuticals Inc (NASDAQ:FENC) Stock Holdings Increased by Bank of New York Mellon Corp - Defense World
Fennec Pharma stock hits 52-week low at $4.96 amid challenges - Investing.com
Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month Low at $7.00 - Defense World
Fennec Pharmaceuticals (TSE:FRX) Reaches New 12-Month Low at $7.00 - MarketBeat
Fennec Pharmaceuticals (NASDAQ:FENC) & Inhibikase Therapeutics (NYSE:IKT) Head to Head Review - Defense World
Acadian Asset Management LLC Makes New Investment in Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
(FENC) Long Term Investment Analysis - Stock Traders Daily
WINTON GROUP Ltd Buys Shares of 67,005 Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals (NASDAQ:FENC) Stock Price Down 4.9% - MarketBeat
Fennec Pharmaceuticals (NASDAQ:FENC) Stock Price Down 4.9% - Defense World
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$18,115.81 in Stock - Defense World
Fennec Pharmaceuticals Inc. (TSE:FRX) Director Sells C$18,115.81 in Stock - MarketBeat
Fennec Pharmaceuticals (TSE:FRX) Hits New 1-Year Low at $7.00 - MarketBeat
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Kincardine News
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - Prince George Post
Fennec Pharmaceuticals to Participate in Upcoming Investor Conferences - StockTitan
Fennec Pharmaceuticals director sells shares worth over $13k - Investing.com
Fennec Pharmaceuticals director sells shares worth over $13k By Investing.com - Investing.com UK
Fennec Pharmaceuticals (TSE:FRX) Shares Cross Below Fifty Day Moving Average of $8.25 - MarketBeat
Fennec Pharmaceuticals Inc Forecasted to Post FY2024 Earnings of ($0.21) Per Share (NASDAQ:FENC) - MarketBeat
Research Analysts Set Expectations for Fennec Pharmaceuticals Inc’s FY2024 Earnings (NASDAQ:FENC) - Defense World
Cantor Fitzgerald Weighs in on Fennec Pharmaceuticals Inc.’s FY2024 Earnings (TSE:FRX) - Defense World
(FENC) Trading Advice - Stock Traders Daily
Fennec Pharma stock target cut, holds rating on slow PEDMARK sales - Investing.com
Fennec Pharmaceuticals (NASDAQ:FENC) Price Target Cut to $13.00 by Analysts at HC Wainwright - MarketBeat
Fennec Pharmaceuticals (NASDAQ:FENC) Price Target Cut to $13.00 by Analysts at HC Wainwright - Defense World
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are Reducing Their Forecasts For This Year - Yahoo Finance
Craig Hallum Lowers Fennec Pharmaceuticals (NASDAQ:FENC) Price Target to $15.00 - Defense World
Capital One Financial Research Analysts Cut Earnings Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) - MarketBeat
Fennec Pharmaceuticals (NASDAQ:FENC) Releases Earnings Results, Misses Expectations By $0.26 EPS - MarketBeat
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Analysts Are More Bearish Than They Used To Be - Simply Wall St
Vanguard Group Inc. Sells 126,437 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) - MarketBeat
FY2027 Earnings Estimate for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Issued By Capital One Financial - Defense World
Fennec Pharmaceuticals Second Quarter 2024 Earnings: Misses Expectations - Yahoo Finance
FY2027 EPS Estimates for Fennec Pharmaceuticals Inc Reduced by Capital One Financial (NASDAQ:FENC) - MarketBeat
Q3 2024 EPS Estimates for Fennec Pharmaceuticals Inc (NASDAQ:FENC) Lowered by Wedbush - Defense World
Vanguard Group Inc. Sells 126,437 Shares of Fennec Pharmaceuticals Inc (NASDAQ:FENC) - Defense World
Brokers Offer Predictions for Fennec Pharmaceuticals Inc’s FY2026 Earnings (NASDAQ:FENC) - Defense World
Fennec Pharmaceuticals (TSE:FRX) Sets New 52-Week Low at $7.49 - MarketBeat
Investing in Fennec Pharmaceuticals Inc (FENC): What You Must Know - Knox Daily
Fennec Pharmaceuticals (NASDAQ:FENC) Price Target Lowered to $15.00 at Craig Hallum - MarketBeat
Fennec Pharmaceuticals Inc. (NASDAQ:FENC) Q2 2024 Earnings Call Transcript - Insider Monkey
Fennec Pharmaceuticals’ (FENC) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Earnings call: Fennec Pharmaceuticals achieved net revenues of $7.3 million - Investing.com India
Q2 2024 Fennec Pharmaceuticals Inc Earnings Call Transcript - GuruFocus.com
Fennec Pharma stock hits 52-week low at $5.38 amid market challenges - Investing.com
Wedbush Reiterates Outperform Rating for Fennec Pharmaceuticals (NASDAQ:FENC) - MarketBeat
Earnings call: Fennec Pharmaceuticals achieved net revenues of $7.3 million - Investing.com
Earnings call: Fennec Pharmaceuticals achieved net revenues of $7.3 million By Investing.com - Investing.com UK
Fennec Pharma stock hits 52-week low at $5.38 amid market challenges - Investing.com Canada
Fennec Pharma stock hits 52-week low at $5.38 amid market challenges - Investing.com Australia
Fennec Pharmaceuticals Inc Stock (FENC) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):